Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review
Journal
American Journal of Transplantation
Journal Volume
8
Journal Issue
10
Pages
2111-2118
Date Issued
2008
Author(s)
Abstract
The precise impact of valganciclovir as preventive therapy for cytomegalovirus (CMV) in solid organ transplant (SOT) recipients is not fully defined. Data from studies using valganciclovir as preemptive therapy or prophylaxis for CMV in SOT recipients were synthesized for descriptive analysis. CMV disease occurred in 2.6% and 9.9% of the patients receiving valganciclovir as preemptive therapy and prophylaxis, respectively. Although the incidence of early-onset (?90 days posttransplant) CMV disease was only 0.8% and 1.2% in all patients and R-/D+ patients receiving valganciclovir prophylaxis, the incidence of late-onset (>90 days posttransplant) CMV disease rose up to 8.9% and 17.7% in the prophylactic group, respectively. On the contrary, no patients developed late-onset CMV disease in preemptive group. Both approaches with valganciclovir have successfully decreased CMV disease in SOT recipients. Late-onset CMV disease is a complication observed uniquely with valganciclovir prophylaxis, particularly in R-/D+ patients, but not with preemptive therapy. ? 2008 The Authors.
SDGs
Other Subjects
alemtuzumab; ganciclovir; OKT 3; thymocyte antibody; valaciclovir; valganciclovir; article; clinical trial; cytomegalovirus infection; drug efficacy; follow up; graft failure; graft rejection; human; infection prevention; infection risk; mortality; organ transplantation; priority journal; systematic review; treatment failure; treatment outcome; virus resistance; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Ganciclovir; Humans; Kidney Diseases; Kidney Transplantation; Liver Diseases; Liver Transplantation; Risk; Time Factors; Transplantation Immunology; Treatment Outcome; Virology
Type
journal article